B
BDTX
Black Diamond Therapeutics, Inc.
2.230
-0.040-1.76%After Hours: 2.230 0.000 0.00%19:30 08/28 EDT
OPEN/PREV CLOSE2.280/2.270
TODAY RANGE2.170-2.290
VOL522.03K
MARKET CAP128.12M
52 WEEK RANGE1.600-4.940
AVG VOL (3M)1.22M
% TURNOVER0.91%
TURNOVER--
P/E (TTM)-2.9941
% RANGE5.28%
EPS(TTM)-0.7448
P/E(FORWARD)-3.6187
P/B1.333
BVPS1.673
DIVIDEND--
P/S1.820
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP126.72M
SHARES OUTSTANDING57.45M
NEXT EARNINGS11/04-11/09
FREE FLOAT56.83M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·08/06 13:56
Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2
TipRanks·08/06 13:18
Black Diamond Therapeutics setup ‘attractive,’ says Jefferies
Seeking Alpha·08/05 21:54
Black Diamond Therapeutics GAAP EPS of -$0.17 beats by $0.03
Benzinga·08/05 20:39
Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate
TipRanks·08/05 20:21
Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c)
Dow Jones·08/05 20:01
*Black Diamond Theraptcs 2Q Loss/Shr 17c >BDTX
Dow Jones·08/05 20:01
Press Release: Black Diamond Therapeutics Reports -2-
Seeking Alpha·07/06 05:51
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Simply Wall St·07/01 10:43
Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth
TipRanks·06/29 20:52
Black Diamond Shareholders Approve Directors and Annual Say-on-Pay
TipRanks·06/01 13:35
Wedbush Remains a Buy on Black Diamond Therapeutics (BDTX)
NASDAQ·05/27 15:16
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
NASDAQ·05/27 15:13
Black Diamond Stock Outlook After Q1 Beat and Cash Runway